Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Excludes permit applications for construction of certain pipelines and related infrastructure from eligibility for automatic approval if DEP fails to take action on application within 90 days.
Establishes certain penalties on clinical laboratories regarding receipt of Medicaid overpayments, and on entities engaged in business with such clinical laboratories.